ecamsule

Trade name: Mexoryl SX

Small moleculeapproved

Approved

Jul 21, 2006

Also called Ecamsule (technical name terephthalylidine dicamphor sulfonic acid), Mexoryl SX is a synthetic sunscreen agent developed and patented by L’Oreal and used in the company’s sunscreen products sold outside the United States since 1993 (approved for use in Europe in 1991). Ecamsule affords broad spectrum protection against the sun’s UVB and UVA rays. Exposed to UV, ecamsule undergoes reversible photoisomerization, followed by photoexcitation. The absorbed UV is then released as thermal energy, without penetrating the skin. The UVB range is 280 to 320 nanometers, and the UVA range is 320 to 400. Ecamsule protects against UV wavelengths in the 290–400 nanometer range, with peak protection at 345 nm.[3][4] Since ecamsule doesn't cover the entire UV spectrum, it should be combined with other active sunscreen agents to ensure broad-spectrum UV protection. Ecamsule is a photostable organic UVA absorber, meaning it doesn't degrade significantly when exposed to light. — NCATS

Clinical trial activity

4 trials · 4 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
1

Earliest trial started May 1, 2006 (NCT00326274)

Timeline

2000s

  1. Jan 1, 2006

    L'Oreal — Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2006

    L'Oreal — Earliest Phase 3 Sponsor(trial)

  3. Jul 21, 2006

    L'Oreal — Earliest FDA Approval

  4. Jul 21, 2006

    L'Oreal — NDA Organization

  5. Jul 21, 2006

    L'Oreal — NDA Secondary Org

  6. Jul 21, 2006

    Sanofi-Aventis — NDA Secondary Org

Indications

Mechanism of action

  • Unspecified targetOTHER

    Sunscreen

  • Unspecified targetUltraviolet filter

    ultraviolet filter

Combination products

Approval history

  • approvedJul 21, 2006

Chemistry & pharmacology

Loading structure…

SMILES

CC1(C)C2CCC1(CS(=O)(=O)O)C(=O)C2=Cc1ccc(C=C2C(=O)C3(CS(=O)(=O)O)CCC2C3(C)C)cc1
Mol. weight
562.71 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Over the Counter

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxobicyclo(2.2.1)heptane-1-methanesulfonic acid)
  • ((3z)-3-((4-((z)-(7,7-dimethyl-3-oxo-4-(sulfomethyl)norbornan-2-ylidene)methyl)phenyl)methylidene)-7,7-dimethyl-2-oxo-norbornan-1-yl)methanesulfonic acid
  • ecamsule
  • ecamsule
  • ecamsule
  • ecamsule
  • ecamsule
  • ecamsule
  • ecamsule
  • mexoryl
  • mexoryl
  • mexoryl sx
  • mexoryl sx
  • mexoryl sx
  • mexoryl sx
  • mexoryl sx
  • mexoryl sx
  • terephthalylidene dicamphor sulfonic acid
  • terephthalylidene dicamphor sulfonic acid
  • terephthalylidene dicamphor sulfonic acid
  • terephthalylidene dicamphor sulfonic acid

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01695356Phase 4Sep 1, 2012Universidad Autonoma de San Luis Potosi
NCT00701740Phase 2Jul 1, 2007University of Sao Paulo
NCT00368563Phase 2/Phase 3 (Phase 3)Aug 1, 2006Hill Top Research, L'Oreal
NCT00326274Phase 3May 1, 2006L'Oreal
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
L'OrealFor profit2212006
Hill Top ResearchFor profit1012006
Universidad Autonoma de San Luis PotosiAcademic/Hospital1112012
University of Sao PauloAcademic/Hospital1112007
4 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
L'OrealFor profitNDAJul 21, 2006
L'OrealFor profitNDA2Jul 21, 2006
Sanofi-AventisFor profitNDA2Jul 21, 2006